Placebo News and Research

RSS

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.

25 Nov 2015

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.

21 Nov 2015

Atypical antipsychotic shows bipolar I depression efficacy

The atypical antipsychotic cariprazine may be effective for the treatment of bipolar I depression, phase II study findings show.

20 Nov 2015

New data shows ALS-008176 drug safe and effective against RSV infection

Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies announced that the New England Journal of Medicine will publish findings from a respiratory syncytial virus (RSV) challenge study for ALS-008176, a cytidine nucleoside analog with activity against RSV.

20 Nov 2015

NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

The National Institute for Health and Care Excellence today issued its Final Appraisal Determination (FAD) recommending Xofigo (radium-223 dichloride) for use on the NHS in England as an option for treating adult men, with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy.

20 Nov 2015

Type II diabetes drug can effectively clear fatty liver disease from some patients

New research published in The Lancet has shown that a drug, currently used in the treatment of Type II diabetes, can be effective in clearing fatty liver disease from some patients.

20 Nov 2015

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.

19 Nov 2015

Sildenafil drug improves insulin sensitivity in people at risk for diabetes

The drug sildenafil, sold as Viagra and other brand names, improves insulin sensitivity in people at risk for diabetes, researchers at Vanderbilt University Medical Center reported today.

19 Nov 2015

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Noguchi explained that immunotherapy has emerged recently as a viable and attractive strategy for the treatment of advanced cancer.

18 Nov 2015

Use of azithromycin early reduces risk of recurrent, severe LRTI among young children

Among young children with histories of recurrent severe lower respiratory tract illness (LRTI), the use of azithromycin early during an apparent RTI compared with placebo significantly reduced the risk of experiencing progression to severe LRTI, according to a study in the November 17 issue of JAMA.

18 Nov 2015

Giving antibiotics early can reduce risk of severe lower respiratory tract illness in children

Respiratory infections are common in preschoolers, but while most children recover fairly easily from the typical coughs and congestion, a significant number develop illnesses severe enough to interfere with breathing and warrant trips to urgent care clinics or emergency rooms.

18 Nov 2015

Vitamin E shows same efficacy in diabetic and nondiabetic patients

There have been numerous studies on the safety and efficacy of using vitamin E to treat nondiabetic patients with nonalcoholic steatohepatitis (NASH), but researchers at the annual meeting of the American Association for the Study of Liver Diseases presented results of vitamin E in diabetic and nondiabetic patients.

17 Nov 2015

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

Haemodynamic variables may distinguish pre- from post-capillary PH

Researchers have identified the haemodynamic variables that best distinguish between patients with idiopathic pulmonary arterial hypertension and isolated post-capillary pulmonary hypertension.

16 Nov 2015

Angina in women linked with abnormal heart blood flow

Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, demonstrated with a drug commonly used to alleviate chest pain patients with coronary artery disease, which was found to be ineffective in patients with moderate female-pattern heart disease, but may offer some relief for sicker patients, a new Cedars-Sinai Heart Institute study shows.

12 Nov 2015

OCD patients can benefit from exposure and response prevention therapy when drug treatment options fail

Patients with Obsessive-Compulsive Disorder (OCD) can improve their symptoms significantly by adding exposure and response prevention therapy to their treatment regimen when common drug treatment options have failed, according to new research from psychiatrists at the Perelman School of Medicine at the University of Pennsylvania.

12 Nov 2015

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on November 10.

11 Nov 2015

Study shows mindfulness meditation reduces pain more effectively than placebo

Scientists at Wake Forest Baptist Medical Center have found new evidence that mindfulness meditation reduces pain more effectively than placebo.

11 Nov 2015

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Data presented yesterday by researchers for Mallinckrodt plc, a leading specialty biopharmaceutical company, suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain measures of disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) who are receiving corticosteroid therapy.

10 Nov 2015

Placebo News and Research

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Atypical antipsychotic shows bipolar I depression efficacy

New data shows ALS-008176 drug safe and effective against RSV infection

NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

Type II diabetes drug can effectively clear fatty liver disease from some patients

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Sildenafil drug improves insulin sensitivity in people at risk for diabetes

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Use of azithromycin early reduces risk of recurrent, severe LRTI among young children

Giving antibiotics early can reduce risk of severe lower respiratory tract illness in children

Vitamin E shows same efficacy in diabetic and nondiabetic patients

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Haemodynamic variables may distinguish pre- from post-capillary PH

Angina in women linked with abnormal heart blood flow

OCD patients can benefit from exposure and response prevention therapy when drug treatment options fail

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

Study shows mindfulness meditation reduces pain more effectively than placebo

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News